Lonza : Doer Biologics signs licensing agreement with Lonza to develop multi-specific biotherapeutics using XS Pichia
December 08, 2021 at 08:12 am EST
Share
Doer Biologics is utilizing its proprietary MultipleBody® and SMART-VHHBody technology platforms for developing multi-specific biotherapeutics to address unmet medical needs
The license agreement will leverage Lonza's XS®Pichia Expression System for the production of this important class of medicines
Basel, Switzerland and Hangzhou, China, 8 December 2021 - Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into a research license agreement for Doer Biologics to use Lonza's XS Technologies® offering for production of its proprietary MultipleBody® and SMART-VHHBody platform technology. Doer Biologics is a clinical-stage biopharmaceutical company focused on the development of multi-domain-based, multi-specific innovative protein drugs in the fields of cancer, endocrinology, metabolic diseases, and ophthalmology.
The license secures Doer Biologics' access to Lonza's XS®Pichia Expression System, providing for the development of scalable, robust, and reliable expression processes. This will enable Doer Biologics to develop, express, and manufacture multi-specific VHH based biotherapeutic proteins to address unmet medical needs in the field of immuno-oncology. Doer Biologics noted early success with the Lonza XS®Pichia Expression System in their lab and are pursuing further developments.
Peter Droc, Head of Licensing and Drug Product Services, Lonza, commented:"Next-generation therapies always demand a new take on expression systems. At Lonza, we have continued developing a toolbox of expression systems that help accommodate industry trends, eliminate production bottlenecks, align downstream processing and drive breakthroughs in the clinic. Doer Biologics has innovative R&D pipelines for VHH antibodies and we believe this agreement will further accelerate their candidates from pre-clinical study to commercial manufacturing."Dr. Yanshan Huang, founder and CEO, Zhejiang Doer Biologics Co. Ltd, added: "Multi-specific biologics often show stronger potency, extended half-life, improved therapeutic window, and higher developability compared to single-target antibodies. However, designing and developing new multi-specific antibodies represents a central challenge for the realization of new immunotherapies. Access to Lonza's proprietary expression technology will enable us to progress our proprietary MultipleBody® and SMART-VHHBody platform by providing high-yielding processes for our candidates. We believe that we can develop high-quality VHH based multi-specific biotherapeutics in a faster and lower-cost fashion with Lonza's XS®Pichia Expression System."
For more details on XS Technologies® visit https://pharma.lonza.com/xstechnologies
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lonza Group Ltd. published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 13:11:05 UTC.
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
LONZA GROUP AG 
